Amicus Therapeutics Announces Second Quarter 2008 Financi...((617) 897-8294Source: FOLD -G Table 1...),Health

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period from

February 4,

2002

(inception)

Three Months Six Months to

Ended June 30, Ended June 30, June 30,

2007 2008 2007 2008 2008

Revenue:

Research

revenue $- $3,113 $- $5,579 $6,954

Collaboration

revenue - 694 - 1,389 1,797

Total revenue - 3,807 - 6,968 8,751

Operating

Expenses:

Research

and

development 6,783 8,848 13,867 15,789 105,667

General

and

administrative 3,189 5,118 6,040 10,305 48,374

Impairment

of leasehold

improvements - - - - 1,030

Depreciation

and amortization 312 332 609 653 3,447

In-process

research and

development - - - - 418

Total operating

expenses 10,284 14,298 20,516 26,747 158,936

Loss from

operations (10,284) (10,491) (20,516) (19,779) (150,185)

Other income

(expenses):

Intere
'/>"/>